HoneyNaps is official in US
By HME News Staff
Updated 9:17 AM CDT, Tue October 8, 2024
BOSTON – HoneyNaps, which is based in South Korea, has delivered its artificial intelligence sleep disorder diagnostic software SOMNUM to two medical institutions in the United States, it announced Oct. 7. "The U.S. is the largest sleep medicine market in the world and still holds significant growth potential,” a company representative said. “As we officially enter the U.S. market, we will solidify our business strategy to achieve a 10% market share within three years." HoneyNaps is currently strengthening its B2B business with major companies in South Korea, while simultaneously selling through its U.S. subsidiary in Boston and its West Coast dealer channels and expects continuous growth in export volume. SOMNUM is an algorithm that analyzes bio signal data during sleep and provides disease diagnoses in under five minutes using its self-developed AI model. The company says the software can be integrated into any medical and health care market using real-time, large-scale bio signal. HoneyNaps recently raised an additional $11.6 million in funding.
Comments